A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma by Kelly, S. et al.
A systematic review of the staging performance of
endoscopic ultrasound in gastro-oesophageal
carcinoma
S Kelly, K M Harris, E Berry, J Hutton, P Roderick, J Cullingworth, L Gathercole,
M A Smith
Abstract
Background—Endoscopic ultrasound
(EUS) may be used for preoperative stag-
ing of gastro-oesophageal carcinoma but
performance values given in the literature
diVer.
Aims—To identify and synthesise findings
from all articles on the performance of
EUS in tumour, node, metastasis (TNM)
staging of gastro-oesophageal carcinoma.
Source—Published and unpublished Eng-
lish language literature, 1981–1996.
Methods—Data on the staging perform-
ance of EUS were retrieved and evaluated.
Summary receiver operator characteris-
tic methodology was used for synthesis,
and a summary estimate of performance,
Q*, obtained. Multiple regression analysis
was used to assess study validity and
investigate reasons for diVerences in per-
formance.
Results—Twenty seven primary articles
were assessed in detail. Thirteen supplied
results for staging oesophageal cancer, 13
for gastric cancer, and four for cancers at
the gastro-oesophageal junction. For gas-
tric T staging, Q*=0.93 (95% confidence
interval (CI) 0.91–0.95) and for oesopha-
geal T staging, Q*=0.89 (95% CI 0.88–
0.92). For gastro-oesophageal T staging,
including cancers at the gastro-
oesophageal junction, Q*=0.91 (95% CI
0.89–0.93). Inclusion of cases with non-
traversable stenosis was found to slightly
reduce staging performance. For N stag-
ing, Q*=0.79 (95% CI 0.75–0.83). In arti-
cles that compared EUS directly with
incremental computed tomography, EUS
performed better. None of the variables
assessed in the regression analysis was
significant using a Bonferroni correction.
Three variables (anatomical location, tra-
versability, and blinding) showed strong
relationships for future research and vali-
dation.
Conclusions—EUS is highly eVective for
discrimination of stages T1 and T2 from
stages T3 and T4 for primary gastro-
oesophageal carcinomas. The failure rate
of EUS from non-traversability of a
stenotic cancer may be a limitation in
some patient groups.
(Gut 2001;49:534–539)
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Accurate staging of gastro-oesophageal cancer
is essential for well informed decisions on stage
dependent patient management. This is be-
coming increasingly important with improve-
ments in non-surgical treatment regimens.
While patients with early localised disease
clearly benefit from complete surgical resec-
tion, there is increasing evidence that multi-
modal treatment (chemoradiotherapy) is supe-
rior to surgery alone for patients with
resectable adenocarcinoma of the oesophagus.1
Accurate local cancer staging provides the
information to allow such important decisions
to be made so as not to deny patients
potentially curative surgical resection, with or
without neoadjuvant therapy, as appropriate.
The development of other non-surgical tech-
niques at both ends of the disease spectrum has
also reinforced the need for accurate cancer
staging. Endoscopic ultrasound (EUS) in con-
junction with endoscopic mucosal resection2 is
only appropriate for superficial non-invasive
cancers. Metal mesh oesophageal stents can be
employed to aVord adequate palliation in
patients with advanced unresectable oesopha-
geal cancer.3
The decision to undertake surgical resection
is complex and based on many factors in addi-
tion to accurate cancer staging, including in
particular the age of the patient and the
presence of significant coexisting medical
problems. Accurate staging is essential in all
patients to allow an informed decision to be
made regarding the most appropriate method
of non-surgical treatment or palliation even in
those considered unfit for surgical interven-
tion. If comparisons of the outcomes of
available and future treatment protocols are to
be made, comparable input data should be
available from all patients. This is particularly
important if the patient does not undergo pri-
mary surgical resection, with the consequent
loss of pathological confirmation, as then the
stage of the cancer can only be assessed from
the best imaging modality or modalities.
EUS has been in use since the early 1980s
but it has been slow to gain acceptance in cer-
tain countries, including the UK. There are
two basic types of echoendoscope commer-
cially available, with either radial or linear array
transducer technology. In addition, miniprobes
are small higher frequency probes that can be
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passed down the biopsy channel of a conven-
tional endoscope. Their high frequency en-
sures excellent resolution but also limited
depth of penetration.
The ability of EUS to identify the compo-
nent layers of the bowel wall provides the basis
for cancer staging within the widely accepted
tumour, node, metastasis (TNM) classifi-
cation. The International Union against Can-
cer (UICC) TNM classification4 defines the
extent of malignant cancer and allows easy
correlation of results from more than one cen-
tre. While broadly similar there are important
diVerences between TNM staging for oesopha-
geal carcinoma and gastric carcinoma. The
definition has recently (1997) been changed5
but all articles included in this review used the
1987 definition.4
A systematic literature review6 of EUS in
gastro-oesophageal carcinoma was undertaken
as part of the NHS Health Technology Assess-
ment Programme. This review addresses a
subset of questions associated with staging
performance. We examine the evidence on the
staging performance of EUS for diVerentiating
cancer stages T1 and T2 from stages T3 and
T4, and lymph node stage N0 from N1 and
N2. Furthermore, we ask if performance diVers
with anatomical location of the primary
carcinoma and how the overall performance is
aVected by the occurrence of non-traversable
stenoses. Finally, the staging performance of
EUS is compared with that of available
computed tomography (CT) techniques.
Methods
DATA SOURCES
Explicit search strategies6 were used to retrieve
information from Medline and BIDS from
1981 to 1996 inclusive. The Cochrane Library,
Embase, the British Library’s Inside and
SIGLE (System for the Identification of Grey
Literature) databases,7 and FirstSearch from
the Online Computer Library Centre8 were
searched using the keywords endoscopic ultra-
sound (or ultrasonography), EUS, and en-
dosonography. Bibliographies of articles re-
trieved were hand searched. Authors of
conference abstracts, leading manufacturers,
major UK centres, and electronic mail discus-
sion groups were contacted with a request for
information on unpublished studies. An update
of the systematic review was conducted in 1999
by searching Medline. This identified any new
literature since completion of the review in
1996 and allowed an estimation of the progress
in the field and any impact on the conclusions.
STUDY SELECTION
Review articles, abstracts, editorials or letters,
case reports, and non-English language articles
were excluded. A second set of exclusion crite-
ria was applied to include only articles discuss-
ing the use of EUS for staging in a study of
gastro-oesophageal carcinoma on human sub-
jects. The final set of criteria concerned more
general quality considerations. Articles were
excluded if they did not provide a comparison
with the gold standard reference test of pathol-
ogy, were duplicate studies on the same patient
group, involved 10 or fewer patients, or did not
supply suYcient information to construct a
2×2 contingency table of results. Two check-
lists were used to extract important infor-
mation for evaluation of study design and
validity. The first checklist concentrated on
potential threats to study validity in terms of
the likely risk of bias. Twenty biases potentially
arising from the design of medical imaging
studies for evaluation of diagnostic perform-
ance were considered.9 The second checklist
was used to note factors that might vary
between studies. These factors included tech-
nical parameters, patient characteristics, and
study design. The number of articles was
expected to be small, so rather than use this
validity information to exclude studies, infor-
mation from the checklists was incorporated
into the data synthesis.10–12 This allowed inves-
tigation of the relative influences of selected
biases and factors on the study results, without
running the risk of excluding too many articles
with over stringent inclusion criteria.
DATA EXTRACTION
Comparison with the gold standard of pathol-
ogy was required. All patients had surgical
exploration and the majority underwent resec-
tion from which a precise pathological stage
could be determined. In a small number of
cases a resection was deemed inappropriate
due to the advanced nature of the tumour.
Data were extracted where results were pre-
sented for staging carcinoma, lymph nodes, or
metastases according to the 1987 TNM
system.4 Corresponding results were taken
from articles that used CT on the same
subjects as were investigated with EUS. To
facilitate calculation of the true positive rate
(TPR) and false positive rate (FPR), 2×2 con-
tingency tables were completed. For cancer
staging the contingency tables were completed
for diVerentiation of stages T1 and T2 from
stages T3 and T4. This threshold was judged
to be of the most clinical significance to aid the
decision between surgical and non-surgical
management of patients. Similarly, for
oesophageal lymph nodes the tables were com-
pleted for diVerentiation of stage N0 from N1
and N2.
QUANTITATIVE DATA SYNTHESIS
A range of TPR/FPR pairs was expected from
the articles included, arising partly from
random variations but also from small diVer-
ences in the way in which the test was
performed. For example, slightly diVering
thresholds may have been applied because of
inter-operator variation or the use of diVerent
equipment. To allow a summary estimate of
test performance the summary receiver operat-
ing characteristic (SROC) methodology first
described by Moses and colleagues10 and Irwig
and colleagues11 12 was applied. This tech-
nique13 involves logistic transformation of the
TPR/FPR pairs to allow linear fitting to the
data. Results are then back transformed and
plotted as a SROC curve.14
For comparison purposes a further statistic,
Q*, the value of TPR where TPR=(1−FPR),
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and its 95% confidence interval (CI)10 were
calculated. This value was obtained from the
intercept of the SROC curve and a line plotting
sensitivity equals specificity. Q* is an appropri-
ate summary statistic for EUS and represents
the optimum performance for the following
reasons. Due to the dichotomy chosen for can-
cer staging, T1 or T2 is analogous to a positive
diagnosis in a conventional 2×2 table, and
therefore T3 or T4 is analogous to a negative
diagnosis. This implies that sensitivity is a
measure of the ability of EUS to correctly stage
T1/T2 and not overstage cancers as T3/T4,
and conversely specificity is a measure of the
ability of EUS to correctly stage T3/T4 and not
understage cancers as T1/T2. Neither under-
staging nor overstaging can be assumed to have
more or less impact than the other: understag-
ing cancer will result in surgical operations
which are unnecessary and overstaging will
result in palliative or non-surgical treatments
when resection may have been possible. The
most appropriate threshold is one which mini-
mises both understaging and overstaging—a
Q* value which balances sensitivity and
specificity.
SROC curves were calculated for the staging
of oesophageal carcinoma, gastric carcinoma,
gastro-oesophageal carcinoma (including car-
cinoma at the cardia), and for lymph node
staging of primary gastro-oesophageal carcino-
mas.
VALIDITY ASSESSMENT
Multiple linear regression analysis15 was per-
formed to determine if any of a set of five of the
factors and biases had a statistically significant
eVect on the fit of the linear model at the 5%
level. Variables assessed were the risks of verifi-
cation bias, withdrawal bias, and blinding bias,
and two factors associated with spectrum bias:
the anatomical location of the primary cancer
and inclusion of patients with non-traversable
cancers. The p value used in the analysis
(p<0.01) represents the adjusted value given
by the Bonferroni correction.16 Although po-
tentially all factors and biases considered on
our checklist could have been included in the
analysis, it would have been counterproductive
to include a large number because of the
inverse relation, given by the Bonferroni
correction, between the number and the p
value required to demonstrate significance.
The variables chosen included the biases
representing the greatest threat to study valid-
ity.17 They also addressed our research ques-
tions about the eVect on the results of
anatomical location and traversability. If statis-
tical significance was found in the forward
stepwise approach, the linear model was used
to fit separate SROC curves to each sub-
group.15 To account for the possibility of type II
error when using the conservative approach of
the Bonferroni adjustment,18 any variables with
a significance level of p<0.05 were reported
and implications were discussed to encourage
further research and validation. The analysis
was performed for both cancer staging results
and lymph node staging results.
Results
Twenty seven articles19–45 remained after the
exclusion criteria had been applied. Thirteen
supplied results for staging oesophageal
carcinoma,19–31 13 for staging gastric
carcinoma,23 25 27 32–41 and four for staging cancer
at the cardia (gastro-oesophageal junction)42–45
(table 1).
GASTRO-OESOPHAGEAL CARCINOMA STAGING
WITH EUS
The SROC curves for oesophageal carcinoma
staging, gastric carcinoma staging, and gastro-
oesophageal carcinoma staging are shown in fig
1, and the calculated values for Q* are also
listed. In the multiple regression analysis none
of the variables had a statistically significant
eVect. Trends were identified for the two
factors related to the patient spectrum: for
anatomical location p=0.02 and for inclusion
of patients with non-traversable cancer
p=0.04. In the latter case, the trend was a
reduction in performance when such patients
were included.
LYMPH NODE STAGING WITH EUS (PRIMARY
GASTRO-OESOPHAGEAL CARCINOMAS)
The SROC curve for lymph node staging of
primary gastro-oesophageal carcinoma is
shown in fig 2. In the multiple regression
analysis none of the variables had a statistically
significant eVect. Three articles (out of 20) that
failed to correctly guard against blinding biases
or to report their precautions showed a trend
towards poorer performance (p=0.02).
Table 1 Ranges of sensitivity and specificity for staging, using endoscopic ultrasound,
reported in the included articles
Category
Sensitivity
range (%)
Specificity
range (%)
Oesophageal carcinoma staging (n=13) 71.4–100 66.7–100
Gastric carcinoma staging (n=13) 67.9–100 87.5–100
Gastro-oesophageal carcinoma staging (n=30) 41.7–100 66.7–100
Lymph node staging of gastro-oesophageal
carcinomas (n=20) 59.5–97.2 40.0–100
Figure 1 Summary receiver operating characteristic
curves for the performance of endoscopic ultrasound for T
staging oesophageal cancer, gastric cancer, and
gastro-oesophageal cancer. TPR, true positive rate; FPR,
false positive rate.
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GASTRO-OESOPHAGEAL CARCINOMA STAGING
WITH EUS IN IMPASSABLE STENOSES
Eleven20 23 25 30 31 36 41–45 of the 27 articles that
met our inclusion criteria for staging perform-
ance stated the proportion of impassable sten-
oses for 13 patient groups (fig 3). Only those
where no attempt at dilatation was made are
included.
GASTRO-OESOPHAGEAL CARCINOMA STAGING
WITH COMPUTED TOMOGRAPHY
Eight articles20 24 26 31 33 37 41 44 compared the stag-
ing performance of EUS directly with that of
incremental CT. Five of these studies20 24 26 33 44
provided statistics comparable with those given
in the EUS articles for T staging and
seven20 24 31 33 37 41 44 for N staging (table 2). No
studies were found comparing EUS with spiral
CT.
Discussion
The diVerence between carcinoma staging per-
formance in gastric and oesophageal regions
was statistically significant. EUS performed
better for staging gastric carcinoma, with a Q*
value of 0.93 (0.91–0.95) compared with 0.89
(0.86–0.92) in the oesophagus. There was no
statistically significant diVerence between
lymph node staging performance for primary
cancer in gastric and oesophageal regions. EUS
was least eVective for lymph node staging
(Q*=0.79 (0.75–0.83)). For comparison how-
ever, and it is emphasised that these values are
not from a systematic review of the literature,
alternative methods do not perform any better.
In spiral CT, for example, the sensitivity for
distinguishing stage N0 from N1 was found to
be 24%, with specificity 100%.46
Methodological diVerences between the pri-
mary studies aVected the results. Some studies
counted all those individuals who underwent
the examination in the total number of
patients, regardless of whether or not the
cancer was traversable. Others defined as the
total number in the study only those for whom
the cancer was traversable. The Q* for a result
calculated only from traversable cancer was
Q*=0.92 (0.90–0.94). A more realistic value, if
all patients actually undergoing the procedure
were included in the 2×2 table, was Q*=0.88
(0.84–0.92). The ubiquity of problems of
traversability is of interest to those considering
using the technique. The percentage of non-
traversable cancers varies greatly from series to
series and in part reflects patient selection.
Published results include non-traversability
rates of up to 45%.24 Hordijk and colleagues45
assessed the influence of cancer stenosis on T
staging accuracy. A lower accuracy (46%) was
reported with cancers that were traversable
with diYculty than those that were traversable
with ease or non-traversable (92% and 82%,
respectively). The authors postulated that the
short focal distance between the transducer
and cancer when just traversable “hampers the
clear visualisation of the wall layers and tumour
penetration depth” as a possible explanation
for the lower accuracy. Miniprobes capable of
traversing all but the tightest of oesophageal
cancers are available. Their limited depth of
penetration restricts their use for TNM staging
as the full extent of the cancer and adjacent
lymph node groups may be beyond their field
of view. This is particularly important as it has
been shown45 that the vast majority (80% plus)
of non-traversable oesophageal cancers are at
least T3. For such cancers it is essential to
determine invasion into adjacent structures
(T4) and fully evaluate the nodal status, inves-
tigations that may be beyond the limitations of
the miniprobe. High frequency miniprobes
allow clearer diVerentiation of the component
layers of the bowel wall and so a more
appropriate application for the miniprobe may
be in the evaluation of localised superficial car-
cinomas with a view to possible local endo-
scopic mucosal resection.
There is little published evidence of the use
of miniprobes in gastro-oesophageal cancer.6
In the time since this review was conducted,
evaluation of the use of miniprobes has been of
primary interest in the literature. An update of
the search of Medline, maintaining the same
Figure 2 Summary receiver operating characteristic curve
for the performance of endoscopic ultrasound for lymph node
staging of oesophageal cancer, gastric cancer, and cardia
cancer. TPR, true positive rate; FPR, false positive rate.
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0 0.1 0.2 0.3 0.4 0.5
FPR
0.6 0.7 0.8 0.9 1
T
P
R
TPR = (1 _ FPR)
Oesophageal
Gastric
Cardia
Figure 3 Percentage of patients undergoing endoscopic
ultrasound examination with a non-traversable cancer.
Taken from 11 articles20 23 25 30 31 36 41–45 on staging of primary
gastro-oesophageal carcinomas included in the review.
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Table 2 Ranges of sensitivity and specificity for staging, using computed tomography,
reported in the included articles
Category Sensitivity range (%) Specificity range (%)
Gastro-oesophageal carcinoma staging (n=5) 40.0–80.0 14.3–97.1
Lymph node staging of gastro-oesophageal
carcinomas (n=7) 40.0–79.3 25.0–66.7
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inclusion criteria, found several studies ad-
dressing the question of the eVectiveness of
miniprobes but varied results were identified.
One study reported no benefit of miniprobes in
oesophageal cancer,47 another showed no ben-
efit for advanced cancers due to ultrasound
attenuation,48 a further study demonstrated
benefit only in early gastric cancers,49 and
another study found higher accuracy rates for
oesophageal T staging and similar rates for N
staging compared with conventional probes.50
The articles comparing EUS and CT
carcinoma staging accuracy included in this
review all suggested the T staging performance
of EUS was superior to that of incremental CT.
To ensure that our comparison of CT and EUS
results was valid we sought articles that
performed both imaging tests on the same set
of patients and compared the results to the
same gold standard. However, the technologi-
cal data presented regarding the CT examina-
tion were often limited or omitted and all arti-
cles included incremental rather than spiral
(helical) CT. It was not possible to be certain
that the CT study had been optimised for the
task. Data from studies comparing the accu-
racy of state of the art spiral CT with that of
EUS are required. It was noted that only one
article20 discussed the complementary roles of
the two modalities.
Updated literature available in Medline up
to and including 1999 shows that the level of
evidence for EUS versus CT has not improved.
No studies were found comparing spiral CT
and EUS in gastro-oesophageal cancer. A small
number of studies reported limited results of
incremental CT alongside EUS for oesopha-
geal staging accuracy. These studies continue
to support the hypothesis that EUS is superior
to CT.51–53
Oesophageal adenocarcinoma is increasing
in incidence and adenocarcinomas of the
oesophagus and stomach are now more com-
monly based at the cardia than in previous
years.54 55 The changing natural history of
gastro-oesophageal adenocarcinoma is impor-
tant if the increase in incidence of carcinomas
based on the gastro-oesophageal junction con-
tinues. Although only four articles were avail-
able, their results suggest that the accuracy of
EUS is lower for carcinomas at the cardia.
There are several possible reasons for this,
including anatomy at this site leading to a ten-
dency to scan obliquely through the bowel wall
and cancer. Such oblique scanning can give rise
to artefactual misrepresentation of the true
depth of penetration. No studies specifically
designed to evaluate EUS in the preoperative T
staging of cardia lesions have appeared in
Medline since completion of the systematic
review in 1996.
This systematic literature review has demon-
strated the high accuracy of EUS in the staging
of gastro-oesophageal carcinoma using the
internationally recognised TNM classification.
The performance diVers for gastric and
oesophageal carcinoma and appears to be
lower for carcinomas at the cardia. This is a
cause for concern because the proportion of
carcinomas in this location is increasing. Some
articles overestimate performance by including
only those patients with traversable cancer.
There is little published evidence comparing
the performance of EUS directly with other
state of the art imaging modalities, or describ-
ing the use of EUS in combination with other
techniques.
Update of the literature review showed a
general inertia in the direction of research in
this field. Most new studies concentrated on
the use of miniprobes or comparison with
incremental CT. The impact of this new
research on the conclusions of the review was
minimal. Very little new information was found
on the key issues identified within the review.
There was no subsequent change in the
conclusions for EUS compared with spiral CT,
the value of EUS in non-traversable cases, or
the likely performance of EUS staging of cardia
lesions. A further update of this review is likely
to be relevant to answer these key questions
within the next few years.
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